Aclaris Historical Cash Flow
| ACRS Stock | USD 4.07 0.25 6.54% |
Analysis of Aclaris Therapeutics cash flow over time is an excellent tool to project Aclaris Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 28.7 M or Depreciation of 1.3 M as it is a great indicator of Aclaris Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Aclaris Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Aclaris Therapeutics is a good buy for the upcoming year.
Aclaris |
About Aclaris Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Aclaris balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Aclaris's non-liquid assets can be easily converted into cash.
Aclaris Therapeutics Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Most accounts from Aclaris Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Aclaris Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aclaris Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Aclaris Stock please use our How to Invest in Aclaris Therapeutics guide.At this time, Aclaris Therapeutics' Change Receivables is comparatively stable compared to the past year.
| 2023 | 2024 (projected) | Change To Inventory | 695.8K | 730.5K | Change To Netincome | 22.7M | 22.0M |
Aclaris Therapeutics cash flow statement Correlations
Click cells to compare fundamentals
Aclaris Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Aclaris Therapeutics cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (21.1M) | (13.9M) | 5.3M | 17.9M | (5.4M) | (5.1M) | |
| Free Cash Flow | (98.1M) | (39.1M) | (52.4M) | (68.2M) | (79.6M) | (83.6M) | |
| Change In Working Capital | (2.7M) | (2.4M) | (1.3M) | (1.2M) | 9.4M | 9.9M | |
| Begin Period Cash Flow | 57.0M | 35.9M | 22.1M | 27.3M | 45.3M | 28.7M | |
| Other Cashflows From Financing Activities | (30.3M) | 10.8M | (1.7M) | 123K | (8K) | (7.6K) | |
| Depreciation | 6.4M | 1.3M | 923K | 797K | 863K | 1.3M | |
| Other Non Cash Items | 734K | 2.4M | 24.3M | 4.7M | (20.3M) | (19.3M) | |
| Capital Expenditures | 1.6M | 453K | 308K | 605K | 1.3M | 803.5K | |
| Total Cash From Operating Activities | (96.4M) | (38.6M) | (52.1M) | (67.6M) | (78.3M) | (82.2M) | |
| Net Income | (161.4M) | (51.0M) | (90.9M) | (86.9M) | (88.5M) | (92.9M) | |
| End Period Cash Flow | 35.9M | 22.1M | 27.3M | 45.3M | 39.9M | 30.8M | |
| Change To Liabilities | (5.1M) | (8.9M) | 4.1M | 960K | 864K | 965.6K | |
| Sale Purchase Of Stock | 207K | 7.7M | (3.1M) | (34K) | (102K) | (96.9K) | |
| Investments | 73.1M | 6.8M | (167.3M) | 12.6M | 46.2M | 48.5M | |
| Net Borrowings | 29.3M | (30M) | 10.9M | (11.5M) | (10.3M) | (9.8M) | |
| Stock Based Compensation | 16.2M | 11.2M | 14.1M | 15.0M | 20.5M | 13.0M | |
| Total Cashflows From Investing Activities | 105.7M | 6.4M | (167.6M) | 12.6M | 14.5M | 15.2M | |
| Change To Operating Activities | 661K | (2.0M) | (5.1M) | (1.7M) | (1.5M) | (1.5M) | |
| Total Cash From Financing Activities | (30.3M) | 18.4M | 225.1M | 72.9M | 26.7M | 25.4M | |
| Change To Netincome | 63.1M | 13.4M | 39.2M | 19.7M | 22.7M | 22.0M | |
| Cash And Cash Equivalents Changes | (21.1M) | (13.9M) | 5.3M | 17.9M | 16.1M | 16.9M | |
| Cash Flows Other Operating | 778K | 1.7M | (5.6M) | (2.3M) | (2.1M) | (2.2M) | |
| Change To Account Receivables | (809K) | 4.9M | 149K | 139K | 186K | 195.3K | |
| Change Receivables | (809K) | 4.9M | 149K | 139K | 159.9K | 167.8K | |
| Issuance Of Capital Stock | 25K | 7.7M | 238.2M | 72.7M | 26.7M | 25.4M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Aclaris Stock Analysis
When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.